Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AXLA Stock Summary
Top 10 Correlated ETFs
AXLA
In the News

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.

Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Health (NASDAQ: AXLA ) stock is taking a beating on Friday after the biotechnology company announced plans for a reverse stock split. According to Axcella Health, shares of AXLA stock are going to undergo a one-for-25 reverse split.

Why Is Axcella Health (AXLA) Stock Down 21% Today?
Axcella Health (NASDAQ: AXLA ) stock is falling on Thursday following its announcement of a new Covid-19 treatment patent. However, it's not that this is bad news for the clinical-stage biotechnology company.

Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.

Why Is Axcella Health (AXLA) Stock Up 280% Today?
A little-known penny stock is among the market's top movers today. Axcella Health (NASDAQ: AXLA ) stock surged by as much as 280% on news that it has been granted an important new patent.

Axcella Health stock rockets on long Covid patent win
Axcella Health Inc (NASDAQ:AXLA) saw its stock rocket some 240% higher in Tuesday's early deals after the small-cap firm announced it had secured a patent for its treatment for ‘long' Covid fatigue. The company, in a statement, said its treatment candidate AXA1125, based on compositions of ‘endogenous metabolic modulators' (otherwise referred to as EMMs) had been granted a patent from the US Patent and Trademark Office.

Why Is Axcella Health (AXLA) Stock Up 68% Today?
Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that would act as a catalyst for today's rally.

Why Is Axcella Health (AXLA) Stock Up 35% Today?
Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid Fatigue treatment currently in development.

Penny Stocks To Buy Now? 7 To Watch With Big News this Week
Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?
AXLA Financial details
AXLA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.18 | -3.61 | -1.85 | -1.76 | -1.52 | |
Operating cash flow per share | -1.86 | -3.07 | -1.57 | -1.42 | -1.28 | |
Free cash flow per share | -1.9 | -3.07 | -1.58 | -1.43 | -1.29 | |
Cash per share | 4.81 | 5.54 | 3.38 | 1.44 | 0.32 | |
Book value per share | 2.94 | 3.62 | 2.37 | 0.58 | 0.08 | |
Tangible book value per share | 2.94 | 3.62 | 2.37 | 0.58 | 0.08 | |
Share holders equity per share | 2.94 | 3.62 | 2.37 | 0.58 | 0.08 | |
Interest debt per share | 1.48 | 1.7 | 0.89 | 0.73 | 0.1 | |
Market cap | 5.7B | 1.67B | 4.12B | 1.99B | 445.72M | |
Enterprise value | 5.65B | 1.6B | 4.07B | 1.99B | 430.73M | |
P/E ratio | -158.09 | -27.79 | -70.04 | -29.67 | -5.41 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -185.67 | -32.7 | -82.76 | -36.73 | -6.41 | |
PFCF ratio | -181.77 | -32.62 | -82.37 | -36.54 | -6.37 | |
P/B Ratio | 117.54 | 27.67 | 54.65 | 90.48 | 107.04 | |
PTB ratio | 117.54 | 27.67 | 54.65 | 90.48 | 107.04 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -172.12 | -27.87 | -75.65 | -32.22 | -6.43 | |
EV to operating cash flow | -183.88 | -31.39 | -81.83 | -36.75 | -6.19 | |
EV to free cash flow | -180.02 | -31.3 | -81.44 | -36.57 | -6.15 | |
Earnings yield | -0.01 | -0.04 | -0.01 | -0.03 | -0.18 | |
Free cash flow yield | -0.01 | -0.03 | -0.01 | -0.03 | -0.16 | |
Debt to equity | 0.51 | 0.41 | 0.33 | 1.14 | 0.52 | |
Debt to assets | 0.3 | 0.26 | 0.23 | 0.43 | 0.11 | |
Net debt to EBITDA | 1.67 | 1.17 | 0.86 | -0.02 | 0.22 | |
Current ratio | 11.62 | 11.02 | 13.79 | 5.42 | 1.21 | |
Interest coverage | 0 | -16.92 | -17.9 | -21.2 | -25.48 | |
Income quality | 0.85 | 0.86 | 0.88 | 0.84 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0 | 0 | 0.01 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.62 | -0.21 | -0.57 | -0.95 | -1.03 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 12 | 17.15 | 9.95 | 4.78 | 1.62 | |
ROIC | -0.44 | -0.69 | -0.56 | -1.36 | -9.2 | |
Return on tangible assets | -0.44 | -0.64 | -0.54 | -1.16 | -4.35 | |
Graham Net | 2.79 | 3.48 | 2.3 | 0.51 | 0.04 | |
Working capital | 73.39M | 83.7M | 99.55M | 44.9M | 3M | |
Tangible asset value | 48.51M | 60.22M | 75.38M | 22.01M | 4.16M | |
Net current asset value | 46.97M | 57.92M | 73.12M | 19.33M | 2.38M | |
Invested capital | 0.51 | 0.41 | 0.33 | 1.14 | 0.52 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.32M | 1.81M | 2.14M | 3.3M | 4.5M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.74 | -1 | -0.78 | -3.05 | -19.78 | |
Capex per share | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.42 | -0.35 | -0.45 | -0.05 | -0.05 | |
Operating cash flow per share | -0.35 | -0.35 | -0.29 | -0.07 | -0.05 | |
Free cash flow per share | -0.36 | -0.36 | -0.29 | -0.07 | -0.05 | |
Cash per share | 0.84 | 0.48 | 0.32 | 0.17 | 0.12 | |
Book value per share | 0.18 | -0.14 | 0.08 | 0.01 | -0.03 | |
Tangible book value per share | 0.18 | -0.14 | 0.08 | 0.01 | -0.03 | |
Share holders equity per share | 0.18 | -0.14 | 0.08 | 0.01 | -0.03 | |
Interest debt per share | 0.55 | 0.54 | 0.05 | 0.02 | 0.02 | |
Market cap | 2.67B | 2.25B | 445.72M | 884.03M | 401.6M | |
Enterprise value | 2.66B | 2.25B | 430.73M | 873.27M | 394.11M | |
P/E ratio | -30.35 | -30.27 | -4.59 | -58.64 | -29.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -143.05 | -121.52 | -28.69 | -173.17 | -109.85 | |
PFCF ratio | -142.76 | -120.19 | -28.65 | -173.17 | -109.85 | |
P/B Ratio | 287.19 | -298.01 | 107.04 | 1.22K | -177.86 | |
PTB ratio | 287.19 | -298.01 | 107.04 | 1.22K | -177.86 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -129.21 | -133.44 | -39.28 | -208.77 | -115.81 | |
EV to operating cash flow | -142.73 | -121.63 | -27.72 | -171.06 | -107.8 | |
EV to free cash flow | -142.44 | -120.3 | -27.69 | -171.06 | -107.8 | |
Earnings yield | -0.01 | -0.01 | -0.05 | 0 | -0.01 | |
Free cash flow yield | -0.01 | -0.01 | -0.03 | -0.01 | -0.01 | |
Debt to equity | 3.02 | -3.65 | 0.52 | 2.46 | -0.62 | |
Debt to assets | 0.56 | 0.9 | 0.11 | 0.14 | 0.15 | |
Net debt to EBITDA | 0.29 | -0.13 | 1.37 | 2.57 | 2.2 | |
Current ratio | 2.59 | 1.23 | 1.21 | 1.05 | 0.8 | |
Interest coverage | -27.42 | -20.64 | -28.42 | 20.21 | 0 | |
Income quality | 0.88 | 1.04 | 0.68 | 1.28 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.46 | -1.56 | -0.16 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.29 | 1.07 | 0.88 | 0.11 | 0.18 | |
ROIC | -0.53 | -0.79 | -2.6 | -0.92 | -6.76 | |
Return on tangible assets | -0.44 | -0.6 | -1.28 | -0.3 | -0.37 | |
Graham Net | 0.07 | -0.25 | 0.04 | 0.01 | -0.04 | |
Working capital | 27.23M | 5.12M | 3M | 646K | -2.27M | |
Tangible asset value | 9.3M | -7.55M | 4.16M | 727K | -2.26M | |
Net current asset value | 3.72M | -11.11M | 2.38M | 502K | -2.27M | |
Invested capital | 3.02 | -3.65 | 0.52 | 2.46 | -0.62 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.42M | 3.81M | 4.17M | 6.43M | 8.27M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -2.37 | 2.46 | -5.83 | -5.18 | 1.51 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AXLA Frequently Asked Questions
What is Axcella Health Inc. stock symbol ?
Axcella Health Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AXLA
Is Axcella Health Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $6. The lowest prediction is $6 and the highest is $6
What is AXLA stock prediction ?
What is Axcella Health Inc. stock quote today ?
Axcella Health Inc. stock price is $10.0801 today.
Is Axcella Health Inc. stock public?
Yes, Axcella Health Inc. is a publicly traded company.